The EpiProColon® assay, FDA-approved in 2016, targets SEPT9 gene methylation for CRC screening, achieving 74% specificity and 96% sensitivity in a meta-analysis of 3202 CRC patients and 7284 controls [105,106,107]. This evidence concerns the gene SEPTIN9 and colorectal carcinoma.